Fig. 1From: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsChange in morning pre-dose trough FEV1 over 12–24 weeks (patients with non-reversible airways and EOS < 300 cells/mm3). Bars are LSM (95% SE). Data analyzed in the mITT population using an efficacy estimand. Treatment comparisons are RR (95% CI). BFF, budesonide/formoterol fumarate dihydrate; BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; BUD/FORM, budesonide/formoterol fumarate dihydrate; FEV1, forced expiratory volume in 1 s; GFF, glycopyrronium/formoterol fumarate dihydrate; LSM, least squares mean; mITT, modified intent-to-treat; SE, standard errorBack to article page